Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 15 of 15 for “"CAR-T cell therapy"”.
-
Multi-Pronged Approach to Understanding the Toxicity Associated with CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy has revolutionised cancer immunotherapy, providing effective treatment for previously untreatable malignancies. Its success, in treat ment of haematological cancers, is now fast-advancing to solid tumours. Though, these efforts are faced with many …
-
Engineering VHH-based chimeric antigen receptor (CAR) T cell therapy for solid tumor treatment
Chimeric antigen receptor (CAR) T cells are a promising cancer therapeutic, as they can specifically redirect the cytotoxic function of a T cell to a chosen target of interest. CAR T cells have been successful in clinical trials against hematological cancers, but have experienced low efficacy …
-
Generation of a novel pan-cancer chemokine receptor-modified CAR-T cell therapy directed towards nfP2X7
CAR-T cell therapy has achieved significant success in the treatment of multiple haematological malignancies. However, solid cancers present challenges such as tumour antigen heterogeneity and complex mechanisms of immune evasion that have limited the translation of CAR-T cell therapies from …
-
Exploring Veto Activity: DNAM-1-CD155 Axis in Overcoming NK Cell-Mediated Allo-Rejection and Applications for CAR-T Cell Therapy
… Miller et al. defined veto activity, it enables cells to target host cytotoxic T lymphocyte (CTL) precursors specific to veto cells' antigens, selectively eliminating anti- donor T cell clones without inducing rejection. By leveraging this unique immune property, two key research aims were …
-
Leveraging Systems Immunology To Understand The Molecular Underpinnings Of Chimeric Antigen Receptor T-Cell Therapy
Chimeric Antigen Receptor (CAR) T-cell therapy is a promising strategy for the treatment of human cancers, and in the last decade has progressed from breakthrough early trials to first in class FDA approvals for B-cell leukemias and lymphomas. Concurrent with the promise and challenges in cancer …
-
Mathematical Modelling of Immuno-Oncology and Related Immunology
<p>Immunotherapy offers new and promising treatments for many different types of cancer, but the problem of how to practically regulate the immune response in a way that allows it to fight cancer without overwhelming patients with potentially fatal inflammatory toxicity has yet to be solved. This …
-
Efficacy of Dual Cd19-Cd79B Car In B-Cell Malignancies
… responses, about 30%-60% of patients with B-cell malignancies relapse following CD19-targeting chimeric antigen receptor (CAR) T cell therapy. CD19 loss is a major cause of relapse and resistance after CD19 CAR T therapy. Dual antigen targeting could overcome resistance due to antigen escape …
-
Development of a canine model to evaluate CAR-T cell subsets
Immunotherapy is a rapidly expanding therapeutic modality in the oncology clinic. Immunotherapy with chimeric antigen receptor (CAR) T cells has demonstrated success in human blood cancers, although relapse occurs in ~50% of patients. In the context of solid tumors, CAR-T cells show only transient …
-
Enhancing Chimeric Antigen Receptor T cell therapy in Mouse EGFRvIII Heterogeneous Glioblastoma
<p>Chimeric antigen receptor (CAR) T cell therapy for glioblastoma remains challenging due to insufficient CAR T cell abundance and antigen-negative tumor cells evading targeting. Unfortunately, most preclinical studies evaluating CAR T cells in glioblastoma use tumors expressing a single antigen, …
-
A Novel, Codon-Based Approach to Preserve On-Tumor Activity and Reduce Off-Tumor Toxicity of Chimeric Antigen Receptor (CAR) T Cells
<p> Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable results in the treatment of various hematological malignancies, ushering in tremendous innovation within the field of immunotherapy and improving patient outcomes. Despite this, CAR-T cell therapy is associated with a …
-
Development and characterisation of a novel chimeric antigen receptor against LGR5
… pathway, is lowly expressed in some stem cell niches and overexpressed in multiple cancers, including pre-B acute lymphoblastic leukaemia (pre-B ALL), hepatocellular carcinoma (HCC) and colorectal cancer (CRC). LGR5 has thus emerged as a promising therapeutic target and has spurred the …
-
Investigating Tumour-Immune Cell Interactions in Paediatric Malignancies
… biomarkers that could guide the accurate use of therapy are lacking. In particular, we lack a complete understanding of interactions between the patient’s immune system and tumour. We hypothesised that biological properties of tumours that do not respond to immunotherapy can be detected prior to …
-
Modulating Immunometabolism to Improve The Activity of Car-Nk Cells Targeting Cd70 In Renal Cell Carcinoma
… of several therapies for metastatic clear cell renal cell carcinoma (ccRCC), disease resistance and relapse are common, and therapies with novel mechanisms of action are urgently needed. Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable responses in hematologic …
-
The role of hypoxia in T cell function and immunotherapy
… a high local metabolic demand depletes immune cells of key metabolites including oxygen. Tumour hypoxia is particularly hostile to antitumour cytotoxic CD8+ T cell function by repressing clonal expansion and by eliciting immune checkpoint mechanisms. However, T cells cultured ex vivo at low …
-
Cytotoxic T lymphocyte biology under the microscope
… out and destroy virally infected or cancerous cells. Incapacitate them and you become severely immunocompromised and riddled with tumours (à la prf1-/- mouse model); enhance them and you can beat previously unbeatable cancers (e.g., CAR T cell therapy). More than this though, they are …